Teledyne Put Its Antitrust Argument in the Press Release, Product by Product
- Teledyne Technologies (NYSE: TDY) will acquire all outstanding shares of Varex Imaging (Nasdaq: VREX) at $18.90 per share in cash, an aggregate transaction value of roughly $1.1 billion including equity awards and net debt as of 3 April 2026. Both boards approved unanimously. Completion is anticipated in early 2027, subject to regulatory approvals and Varex stockholder approval.
- Varex makes X-ray tubes, flat panel and photon counting detectors, high-voltage interconnects and imaging software, sold to global OEM manufacturers. Its end markets run across medical diagnostic imaging, non-destructive inspection, security and vehicle inspection, and analysis and measurement. It employs roughly 2,400 people.
- Teledyne’s executive chairman set out the overlap position in unusual detail, stating that Teledyne makes X-ray detectors but not those suited to high-radiation environments such as oncology, that only Varex supplies advanced photon counting detectors, and that Teledyne has never produced X-ray tubes for radiography, fluoroscopy or computed tomography despite making vacuum electronics including magnetrons.
- Teledyne entered healthcare through Teledyne DALSA in 2011 and expanded with Teledyne e2v in 2017, a long-term supplier of magnetrons to cancer radiotherapy OEMs. Evercore is exclusive financial advisor to Varex. No financial advisor is named for Teledyne.
Deal read
- The timeline agrees with that reading. Early 2027 is roughly five to six months away for a $1.1 billion all-cash transaction between two US-listed companies, unanimously approved on both sides, with no financing condition disclosed. Deals of that shape close faster when nobody expects a question to be asked. The release conditions completion on regulatory approvals in the same breath as stockholder approval, and it is the first of those, not the second, that is setting the calendar.
- Competitive frame: photon counting is what is actually being bought. Mehrabian states that only Varex supplies advanced photon counting detectors for healthcare and industrial inspection, and photon counting is the largest shift in computed tomography detection in decades. Teledyne has been accumulating imaging exposure since DALSA in 2011 and e2v in 2017, both of which brought adjacent physics rather than the tube itself. This transaction hands it the source, the detector and the next detector generation together. Judge it on the detector roadmap rather than on any revenue synergy, because there is no overlap to synergise by the buyer’s own account.
- What to watch, and where this sits. It is the third consolidation of a healthcare component or infrastructure supplier in nine days, after KKR took Integer private at roughly $5.7 billion and Curium agreed to buy Lantheus for up to $8 billion. Different buyers, different structures, one pattern: the layer beneath the brands is being bought while the brands themselves are not. Note also that Evercore advises Varex exclusively and no banker is named for Teledyne, which is consistent with a serial acquirer running its own process, and worth holding when the proxy background section lands.
Read the original source (Teledyne and Varex Imaging) →
GeographyUnited States